Evaluation of indoramin added to oxprenolol and bendrofluazide as a third agent in severe hypertension.
1 Indoramin, an alpha-adrenoreceptor blocking agent has been given as a third agent to patients with severe hypertension treated with adequate doses of a beta-adrenoceptor blocking drug and a thiazide diuretic. 2 A further fall in blood pressure followed the addition of indoramin. With 75 mg twice daily this was on average a fall of 12% of mean arterial pressure in the supine position, 16% standing an 17% after exercise. 3 The rise in blood pressure caused by isometric exercise was not altered by indoramin. 4 Indoramin slowed the heart rate. On 75 mg twice daily the reduction was 14% at rest and 19% after exercise. 5 Side effects of indoramin were sedation, sleep disturbance and vivid dreams.
D001539:Bendroflumethiazide / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D004359:Drug Therapy, Combination; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007211:Indoles / Q000627:therapeutic use*; D007217:Indoramin / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D010096:Oxprenolol / Q000627:therapeutic use*; D012893:Sleep Wake Disorders / Q000139:chemically induced
D007211:Indoles; D007217:Indoramin; D010096:Oxprenolol; D001539:Bendroflumethiazide